Autologous stem cell transplantation for solid tumors in children

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Therapeutics

Background:

• Conventional chemotherapy in pediatric oncology often focuses on dose-effect relationships.
• Megatherapy protocols, utilizing stem cell support, have been developed for advanced childhood solid tumors.
• This approach has been used for over 15 years, particularly in neuroblastoma.

Purpose of the Study:

• To review the rationale and application of megatherapy with stem cell support in pediatric oncology.
• To evaluate the efficacy of dose intensification strategies in treating advanced childhood solid tumors.
• To highlight the need for further research and international collaboration.

Main Methods:

• Review of megatherapy protocols with stem cell support in pediatric oncology.
• Analysis of outcomes in patients with neuroblastoma and other advanced childhood solid tumors treated with dose intensification.
• Comparison of event-free survival rates with conventional treatments.

Main Results:

• Megatherapy followed by autologous stem cell reinfusion shows encouraging results in metastatic neuroblastoma and Ewing's sarcoma.
• An increase of approximately 30% in event-free survival rates has been observed compared to conventional treatments.
• The role of this strategy is not yet proven for most childhood solid tumors, except for metastatic neuroblastoma.

Conclusions:

• Megatherapy with stem cell support offers potential benefits for specific pediatric cancers, notably metastatic neuroblastoma.
• Further large-scale, randomized international studies are urgently required to establish the definitive role and cost-effectiveness of these high-morbidity procedures.
• Addressing the high costs and significant morbidity associated with these treatments is crucial for widespread adoption.